Image from Google Jackets

Asthma medication receives new warning / Diane S. Aschenbrenner

By: Series: American Journal of Nursing. 115 : 1, page 22-23 Publication details: January 2015ISSN:
  • 0002-936X
Subject(s): Summary: The Food and Drug Administration has revised the warnings in the labeling of omalizumab (Xolair), a drug used in the treatment of allergic asthma. Omalizumab's labeling now warns that the drug may carry a slightly elevated risk of cardiovascular complications. Omalizumab is administered every two to four weeks as a subcutaneous injection to patients with moderate-to-severe persistent, allergic asthma and an elevated IgE level and whose allergic asthma symptoms aren't well controlled with corticosteroids.
Item type: Articles
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Current library Call number Status Date due Barcode
Manila Tytana Colleges Library REFERENCE SECTION Bound (Browse shelf(Opens below)) Not For Loan

The Food and Drug Administration has revised the warnings in the labeling of omalizumab (Xolair), a drug used in the treatment of allergic asthma. Omalizumab's labeling now warns that the drug may carry a slightly elevated risk of cardiovascular complications. Omalizumab is administered every two to four weeks as a subcutaneous injection to patients with moderate-to-severe persistent, allergic asthma and an elevated IgE level and whose allergic asthma symptoms aren't well controlled with corticosteroids.

Nursing

There are no comments on this title.

to post a comment.
Manila Tytana Colleges Library | Metropolitan Park, Pres. Diosdado Macapagal Blvd., Pasay City, 1300
Tel.(+63-2) 859-0826 | E-mail library@mtc.edu.ph